Table 4. ANOVA analysis of single agent activity^# or fraction cells affected at 24 hours.

Cell type	HEK-293	TC-32	CHLA-10	T-Test
Antisense Target	0.3 µM	3.0 µM†	0.3 µM	HEK vs TC-32	HEK vs CHLA-10
XAGE1E	−0.09 ± 0.06*	0.19 ± 0.10	0.59 ± 0.18	0.0001	0.0000
CCND1	0.03 ± 0.04	0.05 ± 0.04	0.45 ± 0.07	0.2932	0.0000
RBM11	−0.15 ± 0.05	0.10 ± 0.04	0.37 ± 0.05	0.0000	0.0000
CYP4F22-1	−0.02 ± 0.02	0.13 ± 0.05	0.10 ± 0.07	0.0000	0.0076
CYP4F22-2	−0.02 ± 0.09	0.17 ± 0.07	0.18 ± 0.07	0.0016	0.0023
CYP4F22-3	−0.07 ± 0.04	0.24 ± 0.10	0.06 ± 0.04	0.0000	0.0004
PHGDH-1	0.08 ± 0.08	0.22 ± 0.18	0.34 ± 0.22	0.0337	0.0341
PHGDH-2	0.09 ± 0.03	0.20 ± 0.08	0.30 ± 0.07	0.0006	0.0002
IGFBP2-1	0.03 ±0.07	0.18 ±0.05	0.28 ± 0.11	0.0027	0.0014
IGFBP2-2	0.02 ± 0.02	0.30 ± 0.21	0.25 ± 0.08	0.0007	0.0004
IGFBP2-3	0.03 ± 0.07	0.14 ± 0.04	0.50 ± 0.15	0.0151	0.0002
IGFBP2-4	0.02 ± 0.02	0.19 ± 0.05	0.42 ± 0.16	0.0000	0.0015
ANOVA	F = 3.1; ns	F = 5.6; p < 0.01	F = 9.3; p < 0.01

^#Fraction Dead Cells at 24 hours (FA_{24 hs}); FA_{24 hrs} was calculated for single agents using the fraction of cells lost among 5 replicate samples, corrected to the average fraction of cells lost when treated with the highest a scramble control morpholino (for doses ranging from 0.1 to 3 µM) + 10 µM Endo-Porter; Replicates were and controls were measured in the same 96-well seeded with the identical number of healthy cells 24 hours prior to treatment.

^*HEK293 cells show no significant fraction affected cells at 0.3 µM for any antisense agent.

^†TC-32 cells were resistant to Endo-Porter based morpholino uptake and showed peak cytotoxicity at the 3.0 µM dose delivered with passive uptake. CHLA-10 cells showed peak cytotoxicity at a 0.3 µM dose with Endo-Porter.